Analyst Price Targets — ENTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 1, 2025 2:21 pm | Akash Tewari | Jefferies | $20.00 | $10.88 | TheFly | Enanta upgraded to Buy from Hold at Jefferies |
| June 3, 2025 9:37 am | Roy Buchanan | JMP Securities | $24.00 | $7.19 | TheFly | Enanta price target raised to $24 from $23 at Citizens JMP |
| December 9, 2022 6:10 am | — | H.C. Wainwright | $56.00 | $41.96 | Benzinga | HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56 |
| November 22, 2022 7:39 am | — | RBC Capital | $54.00 | $46.40 | Benzinga | RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54 |
| July 29, 2022 10:32 am | Yasmeen Rahimi | Piper Sandler | $87.00 | $51.28 | TheFly | Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler |
Latest News for ENTA
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at…
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $1.05 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first quarter ended December 31, 2025. “Enanta entered the year with significant momentum, advancing our leading RSV treatment portfolio with preparation for a…
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Insider and Institutional Ownership 95.0% of Enanta
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ENTA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.